andere Bezeichnungen
- medikamentöse Therapie (Zytostatika) von Krebserkrankungen oder Infektionen
- antineoplastische oder antiinfektiöse Chemotherapie
Nebenwirkungen einer Chemotherapie
Die Nebenwirkungen einer Chemotherapie sind häufig Übelkeit und Erbrechen, Erschöpfung, Haarausfall, Schleimhautentzündungen und Blutbildveränderungen.
Hauptwirksame Cannabinoide
- CBC
- CBD (Cannabidiol)
- CBDa
- CBDV
- CBG
- Δ⁹-THC
Studien/Artikel zur Behandlung von Nebenwirkungen einer Chemotherapie mit Cannabis-Medikation
- Delata-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation.
- A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy.
- The antiemetic activity of tetrahydrocannabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy.
- Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol.
- Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo.
- Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol.
- delta 9-Tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancerchemotherapy; a double-blind cross-over trial against placebo.
- Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting.
- Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy.
- Comparative trial of the antiemetic effects of THC and haloperidol.
- Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis.
- Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine.
- Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy.
- Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine.
- THC or Compazine for the cancer chemotherapy patient–the UCLA study. Part II: Patient drug preference.
- Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting.
- Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting.
- Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy.
- Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial.
- Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a double blind study.
- A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues.
- Nabilone: an alternative antiemetic for cancer chemotherapy.
- Nabilone: an effective antiemetic in patients receiving cancer chemotherapy.
- Randomized comparative trial of a new anti-emetic: nabilone, in cancer patients treated with cisplatin.
- Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy.
- A double-blind, controlled trial of nabilone vs. prochlorperazine for refractory emesis induced by cancer chemotherapy.
- A multi-institutional Phase III study of nabilone vs. placebo in chemotherapy-induced nausea and vomiting.
- Nabilone vs. placebo in the treatment of chemotherapy-induced nausea and vomiting in cancer patients.
- Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy.
- A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy.
- Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis.
- Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis.
- Double-blind, randomized, crossover trial of nabilone vs. placebo in cancer chemotherapy.
- Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting.
- Levonantradol in the treatment of nausea and vomiting caused by cytostatic drugs (author’s transl) clinical studies
- A randomised multicentre single blind comparison of a cannabinoid anti-emetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy.
- Dose ranging evaluation of the antiemetic efficacy and toxicity of intramuscular levonantradol in cancer subjects with chemotherapy-induced emesis.
- American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.
- National Comprehensive Cancer Network
- Link Wikipedia (DE)